Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells

References

• Weiguang Y, Dalin L, Lidan X, et al. Association of OX40L Polymorphisms with sporadic breast cancer in northeast Chinese Han population. PLoS One 2012;7:e41277 (1--6)
   Google Scholar
• Kamigaki Y, Kawakami K. Risk of second cancer after initial treatment of breast cancer: an Osaka cancer registry database study. Oncol Lett 2011;2:963–73
   PubMed Web of Science ®Google Scholar
• Balz LM, Bartkowiak K, Andreas A, et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-gamma1 signalling in breast cancer cell migration and dissemination. J Pathol 2012;227:234–44
   PubMed Web of Science ®Google Scholar
• Khoee S, Rahmatolahzadeh R. Synthesis and characterization of pH-responsive and folated nanoparticles based on self-assembled brush-like PLGA/PEG/AEMA copolymer with targeted cancer therapy properties: a comprehensive kinetic study. Eur J Med Chem 2012;50:416–27
   PubMed Web of Science ®Google Scholar
• Tian XH, Wei F, Wang TX, et al. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int J Nanomed 2012;7:1031–41
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2012;66:2873–96
   Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21:797–802
   PubMed Web of Science ®Google Scholar
• Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971–3010
   PubMed Web of Science ®Google Scholar
• Choi SK, Verma M, Silpe J, et al. A photochemical approach for controlled drug release in targeted drug delivery. Bioorg Med Chem 2012;20:1281–90
   PubMed Web of Science ®Google Scholar
• Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to alpha5beta1-expressing MDA-MB-231 breast cancer cells. Langmuir 2012;28:4729–36
   PubMed Web of Science ®Google Scholar
• Reinehr R, Haussinger D. CD95 death receptor and epidermal growth factor receptor (EGFR) in liver cell apoptosis and regeneration. Arch Biochem Biophys 2012;518:2–7
   PubMed Web of Science ®Google Scholar
• Milella M, Nuzzo C, Bria E, et al. EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol 2012;7:672–80
   PubMed Web of Science ®Google Scholar
• Lamy PJ, Jacot W. Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagn Pathol 2012;7:13--14
   PubMed Web of Science ®Google Scholar
• Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 2012;11:492–502
   PubMed Web of Science ®Google Scholar
• Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011;55:685–96
   PubMed Web of Science ®Google Scholar
• Stella GM, Luisetti M, Inghilleri S, et al. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respir Med 2012;106:173–83
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Meadows KL, Uronis HE, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 2012;70:95–102
   PubMed Web of Science ®Google Scholar
• Shen Y, Yang J, Xu Z, et al. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis. World J Gastroenterol 2012;18:2712–18
   PubMed Web of Science ®Google Scholar
• Altintas I, Kok RJ, Schiffelers RM. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur J Pharm Sci 2012;45:399–407
   PubMed Web of Science ®Google Scholar
• Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 2012;32:166–215
   PubMed Web of Science ®Google Scholar
• Rahman MA, Amin AR, Wang X, et al. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Rel 2012;159:384–92
   PubMed Web of Science ®Google Scholar
• Kundu AK, Chandra PK, Hazari S, et al. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm 2012;80:257–67
   PubMed Web of Science ®Google Scholar
• Kneidinger D, Ibrisimovic M, Lion T, Klein R. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Res 2012;94:195–207
   PubMed Web of Science ®Google Scholar
• Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012;19:60–71
   PubMed Web of Science ®Google Scholar
• Zhang C, Montgomery TA, Fischer SE, et al. The Caenorhabditis elegans RDE-10/RDE-11 complex regulates RNAi by promoting secondary siRNA amplification. Curr Biol 2012;22:881–90
   Google Scholar
• Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012;320:130–7
   PubMed Web of Science ®Google Scholar
• Zhao S, Ma D, Dai H, et al. Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells. Arch Gynecol Obstet 2011;284:1533–41
   PubMed Web of Science ®Google Scholar
• Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011;6:1130–46
   PubMed Web of Science ®Google Scholar
• Shen Y. Advances in the development of siRNA-based therapeutics for cancer. Drugs 2008;11:572–8
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215–36
   PubMed Web of Science ®Google Scholar
• Astier A, Doat B, Ferrer MJ, et al. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res 1988;48:1835–41
   PubMed Web of Science ®Google Scholar
• Liu CW, Lin WJ. Polymeric nanoparticles conjugate a novel heptapeptide as an active targeting ligand for doxorubicin. Inter J Nanomed 2012;7:4749–67
   PubMed Web of Science ®Google Scholar
• Tahara K, Sakai T, Yamamoto H, et al. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008;354:210–16
   PubMed Web of Science ®Google Scholar
• Song S, Liu D, Peng J, et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 2009;23:1396–404
   PubMed Web of Science ®Google Scholar
• Tseng CL, Wang TW, Dong GC, et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007;28:3996–4005
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Xie SX, Baoum A, et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009;37:141–50
   PubMed Web of Science ®Google Scholar
• Mendoza-Espinoza MCLaJA. Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle. African J Pharm Pharmacol 2011;5:322–6
   Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006;23:1417–50
   PubMed Web of Science ®Google Scholar
• Itabashi H, Maesawa C, Oikawa H, et al. Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Res 2008;38:601–13
   PubMed Web of Science ®Google Scholar
• Shirako E, Hirayama N, Tsukada Y, et al. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation. J Cell Biochem 2008;104:176–88
   PubMed Web of Science ®Google Scholar
• Kolonin MG, Bover L, Sun J, et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 2006;66:34–40
   PubMed Web of Science ®Google Scholar
• Longva KE, Pedersen NM, Haslekas C, et al. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116:359–67
   PubMed Web of Science ®Google Scholar
• He X, Ota T, Liu P, et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010;70:3109–18
   PubMedGoogle Scholar
• Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012;83:1021–32
   PubMed Web of Science ®Google Scholar
• Li YT, Chua MJ, Kunnath AP, Chowdhury EH. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomed 2012;7:2473–81
   PubMedGoogle Scholar
• Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 2002;19:1488–94
   PubMed Web of Science ®Google Scholar
• Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007;59:748–58
   PubMed Web of Science ®Google Scholar
• Tahara K, Yamamoto H, Hirashima N, Kawashima Y. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 2010;74:421–6
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 2005;19:1978–85
   PubMed Web of Science ®Google Scholar
• Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharma 2008;363:155–61
   PubMed Web of Science ®Google Scholar
• Gillies ER, Fréchet JM. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 2005;16:361–8
   PubMed Web of Science ®Google Scholar
• Kim J, Lee YJ, Shin DS, et al. Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell. Bioorg Med Chem 2011;19:7582–9
   PubMed Web of Science ®Google Scholar
• Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158:1757–65
   PubMed Web of Science ®Google Scholar
• Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:4349–54
   PubMed Web of Science ®Google Scholar
• Zhou J, Gan N, Zhang W, et al. Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor. J Obstet Gynaecol Res 2010;36:232–8
   PubMed Web of Science ®Google Scholar
• Huang HY, Kuo WT, Chou MJ, Huang YY. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mater Res A 2011;97A:330--338
   Web of Science ®Google Scholar
• Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010;285:22639–50
   PubMed Web of Science ®Google Scholar